Pharmaceutical interventions for weight-loss maintenance: No effect from cabergoline
posted by WM Admin on 15 August 2018
Year of Publication
International Journal of Obesity, 6 August [Epub before print]
Journal article (peer reviewed)
The authors tested the hypothesis that dopamine agonist treatment would prevent weight regain following acute weight loss in individuals with obesity. The 2-year double blind randomised controlled trial compared the effect of a dopamine agonist, cabergoline, with placebo on weight regain in obese individuals who had lost at least 5% of their body weight using an 800 kcal/day commercial meal replacement programme. They conclude that "treatment with the dopamine agonist cabergoline does not prevent weight regain in obese individuals following weight loss".
Type of Study
Randomised controlled trial
How to Access
To read the full abstract and for information on how to access the full text, go to: https://doi.org/10.1038/s41366-018-0165-3 or contact your DHB library, or organisational or local library for assistance.